BIOMARKERS AND METHODS TO DISTINGUISH OVARIAN CANCER FROM BENIGN TUMORS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Apr 6, 2017
app pub date -
Oct 6, 2016
filing date -
Oct 6, 2015
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Methods for detecting and measuring metabolic changes useful in the detection of cancer, and in differentiating between ovarian cancer and benign ovarian tumor are described, as well as the unexpected and valuable combination of detecting both lipidomic and aqueous metabolites. Two independent LC-MS-based metabolomics platforms, including a global lipidomics approach, were used to screen for differentially abundant plasma metabolites between cases with serous ovarian carcinoma and controls with benign serous ovarian tumor. The identified biomarkers can be used to distinguish between ovarian cancer and benign tumors. Standards and kits for use with the methods for detecting cancer are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully